Cosmos Health Inc. (COSM)

NCM – Real vaqt narxi. Valyuta: USD

0.31

+0.00 (0.13%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a request for withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-283910), originally filed on December 18, 2024 and last amended on June 3, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.

11.05.2026

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18™ to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Fort18™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products.

08.05.2026

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 report EPS outlook upgraded: Zacks now expects Cosmos Health to cross into positive EPS territory in 2026 $4.50 valuation reaffirmed: Updated report maintains valuation target, citing improving fundamentals and operational momentum Long-term growth trajectory maintained: Zacks continues to project revenue of approximately $130.8 million in 2027 "Clear inflection point": Zacks highlights Cosmos Health's accelerating operational momentum and strategic evolution into a higher-margin healthcare platform with multiple growth vectors CHICAGO, IL / ACCESS Newswire / May 8, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research has published an updated research report raising its 2026 revenue and EPS forecasts, while reaffirming its $4.50 per share valuation. The updated report projects revenue growth from a record $65.3 million in fiscal year 2025 to $103.2 million in 2026 - up from Zacks' prior forecast of $98.6 million issued in January 2026 - with further expansion to approximately $130.8 million in 2027.

30.04.2026

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Cur18™ is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products.

21.04.2026

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meet Three products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic support, and inflammation & mobility across three of the fastest-growing health categories in the U.S. Institutional-grade scientific standard: Patented ingredients, published randomized controlled trials, exact clinical dosing - built to the standard of institutional science, not marketing Compounding platform value, 18 clinically validated products targeted: Each new "18" product retroactively strengthens every existing one - the portfolio becomes more valuable with every addition CHICAGO, IL / ACCESS Newswire / April 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the U.S. introduction of the "18 Series" - a premium nutraceutical platform designed to meet growing consumer demand for clinically validated health solutions. 1. The 18 Series - Overview Cosmos Health Inc. is executing a disciplined, science-first strategy to build the what we believe to be most credible clinical supplement portfolio in the United States.

20.04.2026

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk $5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross margins Direct-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocation Early U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a commercial and financial update on Liv18™, its clinically validated liver health supplement, as the Company accelerates its expansion across the United States. The Company has successfully completed Phase 1 execution for Liv18™ (defined as product development, packaging, and initial commercial setup) ahead of schedule.

17.04.2026

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

11.05.2026

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

08.05.2026

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

30.04.2026

Cosmos Health Inc. (COSM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cosmos Health Inc. (COSM)

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Videolar

No Data

Press-relizlar

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Videolar

No Data

Press-relizlar

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Search stocks

Cosmos Health Inc. (COSM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cosmos Health Inc. (COSM)

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Videolar

No Data

Press-relizlar

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Videolar

No Data

Press-relizlar

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months